News and Announcements
Shivom’s Presale is now Live! Sign up now & Complete KYC for Crowdsale
- Published April 16, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Today, April 16th, 2018 marks the launch of Shivom’s presale and an essential step in our journey. We are so thrilled and invite all of you (in case you still have not) to sign up for the public presale event! The public presale will continue until April 22nd, 2018, so don’t miss your chance to register and complete KYC early!
The Shivom OmiX presale event can be found at: https://tokensale.
Why sign up for the Shivom Presale?
We are offering an early bird advantage to everyone who has signed up for the Presale:
-
Sale of the first 15 000 ETH worth of tokens at 10% discount on 16th April. This bonus will decrease by 1% each day.
-
Last chance to buy OmiX tokens at 1 ETH = 7000 OmiX
Registration is free, simple, and fully secured. Every user will have to complete KYC before being eligible for the purchase of OmiX tokens.
If you have already registered for the presale through our platform, make sure your KYC is completed. KYC is not required to purchase tokens, but it is required to obtain your purchased tokens during token distribution.
So grab this opportunity while you still can and join the Shivom community to help transform the future of global healthcare and precision magazine.
Register here.
About Shivom
Shivom combines blockchain, A.I., DNA sequencing & cryptography to enable secure and personalized medicine. The Shivom platform works on collaboration & integrity, allowing people to own, manage and monetize their data. By creating a web-marketplace, a network of genomic counsellors, and a not-for-profit drug research unit, Shivom will build a global healthcare ecosystem, reaching even low-income countries.
Company Updates
The Biofilm Breakthrough: How An Australian BioTech Firm Is Tapping Indonesia’s $45,000-a-Kitchen Bottleneck
Australian sustainability and deep-tech firm Altair International Pty Ltd is commercialising plant-based clinical hygiene technology, targeting a prime operational bottleneck in Indonesia’s massive national free meals program. Every few years, an Australian deep-tech company emerges combining proprietary science with a transformational anchor contract, the kind of business that quietly creates an entirely new market category […]
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Backed By Leading Investment Groups and Family Offices
